Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function. Thus, tofacitinib therapy may result in suppression of multiple elements...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Res Ther
Главные авторы: Strand, Vibeke, Ahadieh, Sima, French, Jonathan, Geier, Jamie, Krishnaswami, Sriram, Menon, Sujatha, Checchio, Tina, Tensfeldt, Thomas G., Hoffman, Elaine, Riese, Richard, Boy, Mary, Gómez-Reino, Juan J.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704538/
https://ncbi.nlm.nih.gov/pubmed/26669566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0880-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы